Arterial and venous plasma levels of bupivacaine following peripheral nerve blocks.
Mean arterial plasma (MAP) and peripheral mean venous plasma (MVP) levels of bupivacaine were ascertained in 3 groups of 10 patients each for: (1) intercostal nerve block, 400 mg; (2) block of the sciatic, femoral, and lateral femoral cutaneous nerves, with or without block of the obturator nerve, 400 mg; and (3) supraclavicular brachial plexus block, 300 mg. MAP levels were consistently higher than simultaneously sampled MVP levels, the highest levels occurring from bilateral intercostal nerve block. No evidence of systemic toxicity was observed. The results suggest that bupivacaine has a much wider margin of safety in humans than is now stated.
D000368:Aged; D001158:Arteries; D001917:Brachial Plexus / Q000187:drug effects; D002045:Bupivacaine / Q000009:adverse effects / Q000097:blood* / Q000494:pharmacology; D004348:Drug Labeling; D004837:Epinephrine / Q000494:pharmacology; D005267:Femoral Nerve / Q000187:drug effects; D006801:Humans; D007367:Intercostal Nerves / Q000187:drug effects; D008297:Male; D009407:Nerve Block; D010525:Peripheral Nerves / Q000187:drug effects*; D012584:Sciatic Nerve / Q000187:drug effects; D012768:Shivering; D012867:Skin / Q000294:innervation; D014680:Veins
D002045:Bupivacaine; D004837:Epinephrine